Advertisement

Sports Medicine

, Volume 37, Issue 4–5, pp 389–391 | Cite as

Blood Doping

Infusions, Erythropoietin and Artificial Blood
Conference Paper

Abstract

As science marches on, athletes and coaches march close behind. Researchers have long been interested in how red cell mass and blood volume affect exercise capacity. Interest in blood doping soared after the 1968 Mexico City Olympics. Studies in the 1970s and 1980s suggested that transfusing red cells could speed endurance performance. Diverse athletes of the time were accused of blood doping. In the late 1980s, recombinant human erythropoietin (EPO) began to supplant transfusion for doping. EPO use is a suspect in nearly 20 deaths in 4 years in European cyclists. In the 1998 Tour de France, a team was ejected for using EPO and six other teams quit the race. The beat goes on; in recent years, diverse endurance and sprint athletes have been caught or accused of using EPO. Tests to detect EPO are improving but are not yet foolproof. As EPO tests improve, blood transfusion is back in vogue and some athletes may have infused artificial blood. Tests for detecting artificial blood also exist, but it seems it will take widespread, year-round, unannounced, out-of-competition testing and stern penalties to deter blood doping.

Keywords

Oxygen Carrier Hydroxyethyl Starch Recombinant Human Erythropoietin Blood Doping Olympic Winter Game 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Eichner ER. Better dead than second. J Lab Clin Med 1992; 120: 359–60Google Scholar
  2. 2.
    Eichner ER. Blood doping: results and consequences from the laboratory and the field. Phys Sportsmed 1987; 15 (1): 121–9Google Scholar
  3. 3.
    Elblom B, Goldbarg AN, Gullbring B. Response to exercise after blood loss and reinfusion. J Appl Physiol 1972; 33: 175–80Google Scholar
  4. 4.
    Eichner ER. Sports anemia, iron supplements, and blood doping. Med Sci Sports Exerc 1992; 24: S315–8PubMedGoogle Scholar
  5. 5.
    Birkeland KI, Stray-Gundersen J, Hemmersbach P, et al. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc 1999; 32: 1238–43Google Scholar
  6. 6.
    Scott J, Phillips GC. Erythropoietin in sports: a new look at an old problem. Curr Sports Med Rep 2005; 4: 224–6PubMedGoogle Scholar
  7. 7.
    Eichner ER. Finding a way: rationalizing erythropoietin in sports. Sports Med Digest 2002; 24 (6): 61–3Google Scholar
  8. 8.
    Parisotta R, Wu M, Ashenden MJ, et al. Detection of recombinant human erythropoietin abuse in athletes utilizing markers of altered erythropoiesis. Haematologica 2001; 86: 128–37Google Scholar
  9. 9.
    Lasne F, de Ceaurriz J. Recombinant erythropoietin in urine. Nature 2000; 405: 635PubMedCrossRefGoogle Scholar
  10. 10.
    Gaudard A, Varlet-Marie E, Bressolle F, et al. Drugs for increasing oxygen transport and their potential use in doping: a review. Sports Med 2003; 33: 187–212PubMedCrossRefGoogle Scholar
  11. 11.
    Lasne F, Crepin N, Ashenden M, et al. Detection of hemoglobin-based oxygen carriers in human serum for doping analysis: screening by electrophoresis. Clin Chem 2004; 50: 410–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Health Sciences CenterUniversity of OklahomaOklahoma CityUSA

Personalised recommendations